

Craig J Thomas

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2101320/craig-j-thomas-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43
papers

4,919
citations

24
h-index

48
g-index

48
ext. papers

6,098
ext. citations

14.1
avg, IF

4.79
L-index

#	Paper	IF	Citations
43	Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2S)- and (1S)-Methyl-(2S)-hydroxynorketamines.. <i>ACS Chemical Neuroscience</i> , 2022 ,	5.7	1
42	Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications. <i>Pharmacological Reviews</i> , 2021 , 73, 763-791	22.5	17
41	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. <i>Cancer Cell</i> , 2021 , 39, 566-579.e7	24.3	24
40	Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 307-319	6.1	7
39	Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo. <i>Microorganisms</i> , 2021 , 9,	4.9	3
38	Overcoming Acquired Epigenetic Resistance to BTK Inhibitors. <i>Blood Cancer Discovery</i> , 2021 , 2, 630-647	7	3
37	KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. <i>Neuro-Oncology Advances</i> , 2020 , 2, i62-i74	0.9	6
36	Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. <i>Journal of Clinical Investigation</i> , 2020 , 130, 2017-2023	15.9	11
35	Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer. <i>Cancer Research</i> , 2020 , 80, 5380-5392	10.1	4
34	Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments. <i>Genes Chromosomes and Cancer</i> , 2020 , 59, 472-483	5	2
33	Overcoming adaptive therapy resistance in AML by targeting immune response pathways. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	25
32	(S)-hydroxynorketamine exerts mGlu receptor-dependent antidepressant actions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 6441-6450	11.5	73
31	(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses. <i>British Journal of Pharmacology</i> , 2019 , 176, 2573-2592	8.6	38
30	Antidepressant-relevant concentrations of the ketamine metabolite (2,6)-hydroxynorketamine do not block NMDA receptor function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 5160-5169	11.5	77
29	Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	64
28	Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (S)-hydroxynorketamine. <i>Journal of Psychopharmacology</i> , 2019 , 33, 12-24	4.6	21
27	Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures. <i>Journal of Infectious Diseases</i> , 2018 , 218, S672-S678	7	38

26	Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells. <i>Scientific Data</i> , 2018 , 5, 180106	8.2	14
25	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. <i>Nature</i> , 2018 , 560, 387-391	50.4	172
24	Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. <i>Pharmacological Reviews</i> , 2018 , 70, 621-660	22.5	395
23	Zanos et al. reply. <i>Nature</i> , 2017 , 546, E4-E5	50.4	21
22	Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. <i>Cancer Cell</i> , 2017 , 31, 833-843	24.3	5279
21	Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites. <i>Organic Letters</i> , 2017 , 19, 4572-4575	6.2	38
20	Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. <i>Nature</i> , 2017 , 549, 533-537	50.4	185
19	Apilimod. <i>IUCrData</i> , 2017 , 2,	0.7	4
18	A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancer Cell</i> , 2016 , 30, 764-778	24.3	84
17	Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants. <i>Retrovirology</i> , 2016 , 13, 11	3.6	9
16	Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 1624-9	11.5	30
15	NMDAR inhibition-independent antidepressant actions of ketamine metabolites. <i>Nature</i> , 2016 , 533, 481-485	50.4	903
14	Cancer network activity associated with therapeutic response and synergism. <i>Genome Medicine</i> , 2016 , 8, 88	14.4	5
13	High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations. <i>Scientific Reports</i> , 2015 , 5, 13891	4.9	69
12	RUC-4: a novel $\beta\beta$ antagonist for prehospital therapy of myocardial infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014 , 34, 2321-9	9.4	47
11	Blockade of oncogenic B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 11365-70	11.5	127
10	Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014 , 24, 630-5	2.9	11
9	High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 2349-54	11.5	270

- 8 Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. *Cancer Cell*, **2013**, 24, 90-104 24.3 140
- 7 Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. *Cancer Cell*, **2012**, 21, 723-37 24.3 386
- 6 Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. *Nature*, **2010**, 463, 88-92 50.4 1149
- 5 Tuning the optical properties of fluorinated indolylfulgimides. *Journal of Organic Chemistry*, **2003**, 68, 319-26 4.2 42
- 4 Optical and thermal properties of photochromic fluorinated adamantylidene indolylfulgides. *Journal of Photochemistry and Photobiology A: Chemistry*, **2002**, 147, 39-44 4.7 19
- 3 Optical properties of photochromic fluorinated indolylfulgides. *Journal of Photochemistry and Photobiology A: Chemistry*, **2001**, 144, 83-91 4.7 54
- 2 Improved synthesis of indolyl fulgides. *Journal of Organic Chemistry*, **2001**, 66, 1914-8 4.2 34
- 1 Thermolysis of a fluorinated indolylfulgide features a novel 1,5-indolyl shift. *Journal of Organic Chemistry*, **2001**, 66, 4739-41 4.2 15